Chronic deteriorating renal function and renal fibrosis

Contributions to Nephrology

Volumn 159, Issue , 2008, Pages 109-121

  Isaka, Y ^a   Takahara, S ^a   Imai, E ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CONNECTIVE TISSUE GROWTH FACTOR; IMMEDIATE EARLY PROTEIN; PLATELET DERIVED GROWTH FACTOR; RIBOZYME; SCATTER FACTOR; SIGNAL PEPTIDE; TRANSCRIPTION FACTOR;

CHRONIC KIDNEY FAILURE; DISEASE COURSE; FIBROSIS; GENE THERAPY; GENETICS; HUMAN; METHODOLOGY; PATHOLOGY; REVIEW; RNA INTERFERENCE;

DISEASE PROGRESSION; FIBROSIS; GENE THERAPY; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY FAILURE, CHRONIC; OLIGONUCLEOTIDES, ANTISENSE; PLATELET-DERIVED GROWTH FACTOR; RNA INTERFERENCE; RNA, CATALYTIC; TRANSCRIPTION FACTORS;

EID: 48549103449     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000125668     Document Type: Review

References (56)

1. Border W, Noble N: Transforming growth factor in tissue fibrosis. N Engl J Med 1994;331:1286-1292.
2. Border WA, Ruoslahti E: Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest 1992;90:1-7.
3. Okuda S, Languino LR, Ruoslahti E, et al: Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. J Clin Invest 1990;86:453-462.
4. Tomooka S, Border WA, Marshall BC, et al: Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int 1992;42:1462-1469.
5. Yamamoto T, Nakamura T, Noble NA, et al: Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993;90:1814-1818.
6. Yamamoto T, Noble NA, Miller DE, et al: Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int 1994;45:916-927.
7. Wrana JL, Attisano L, Wieser R, et al: Mechanism of activation of the TGF-beta receptor. Nature 1994;370:341-347.
8. Kavsak P, Rasmussen RK, Causing CG, et al: Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 2000;6:1365-1375.
9. Akagi Y, Isaka Y, Arai M, et al: Inhibition of TGF-beta1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1996;50:148-155.
10. Isaka Y, Tsujie M, Ando Y, et al: Transforming growth factor-beta 1 antisense oligodeoxynucleotides block interstitial fibrosis in unilateral ureteral obstruction. Kidney Int 2000;58:1885-1892.
11. Ohkawa J, Koguma T, Kohda T, et al: Ribozymes: from mechanistic studies to applications in vivo. J Biochem 1995;118:251-258.
12. Tahira Y, Fukuda N, Endo M, et al: Chimeric DNA-RNA hammerhead ribozyme targeting transforming growth factor-beta1 mRNA ameliorates renal injury in hypertensive rats. J Hypertens 2007;25:671-678.
13. Santiago F, Lowe H, Kavurma M, et al: New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nat Med 1999;5:1264-1269.
14. Santoro SW, Joyce GF: A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci USA 1997;94:4262-4266.
15. Isaka Y, Nakamura H, Mizui M, et al: DNAzyme for TGF-β suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 2004;66:586-590.
16. Fire A, Xu S, Montgomery MK, et al: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-811.
17. Elbashir SM, Harborth J, Lendeckel W, et al: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-498.
18. Takabatake Y, Isaka Y, Mizui M, et al: Exploring RNA interference as a therapeutic strategy for renal disease. Gene Ther 2005;12:965-973.
19. Kushibiki T, Nagata-Nakajima N, Sugai M, et al: Delivery of plasmid DNA expressing small interference RNA for TGF-beta type II receptor by cationized gelatin to prevent interstitial renal fibrosis. J Control Release 2005;105:318-331.
20. Maeshima Y, Kashihara N, Yasuda T, et al: Inhibition of mesangial cell proliferation by E2F decoy oligodeoxynucleotide in vitro and in vivo. J Clin Invest 1998;101:2589-2597.
21. Tomita N, Morishita R, Lan HY, et al: In vivo administration of a nuclear transcription factor-kappaB decoy suppresses experimental crescentic glomerulonephritis. J Am Soc Nephrol 2000;11:1244-1252.
22. Morishita R, Gibbons GH, Horiuchi M, et al: Role of AP-1 complex in angiotensin II-mediated transforming growth factor-beta expression and growth of smooth muscle cells: using decoy approach against AP-1 binding site. Biochem Biophys Res Commun 1998;243:361-367.
23. Ahn JD, Morishita R, Kaneda Y, et al: Transcription factor decoy for AP-1 reduces mesangial cell proliferation and extracellular matrix production in vitro and in vivo. Gene Ther 2004;11:916-923.
24. Fukasawa H, Yamamoto T, Togawa A, et al: Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. Proc Natl Acad Sci USA 2004;101:8687-8692.
25. Sato M, Muragaki Y, Saika S, et al: Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003;112:1486-1494.
26. Hayashi H, Abdollah S, Qiu Y, et al: The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Cell 1997;89:1165-1173.
27. Hou CC, Wang W, Huang XR, et al: Ultrasound-microbubble-mediated gene transfer of inducible Smad7 blocks transforming growth factor-beta signaling and fibrosis in rat remnant kidney. Am J Pathol 2005;166:761-771.
28. Ka SM, Huang XR, Lan HY, et al: Smad7 gene therapy ameliorates an autoimmune crescentic glomerulonephritis in mice. J Am Soc Nephrol 2007;18:1777-1788.
29. Lan HY, Mu W, Tomita N, et al: Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol 2003;14:1535-1548.
30. Terada Y, Hanada S, Nakao A, et al: Gene transfer of Smad7 using electroporation of adenovirus prevents renal fibrosis in post-obstructed kidney. Kidney Int 2002;61:94-98.
31. Schaefer L, Macakova K, Raslik I, et al: Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction. Am J Pathol 2002;160:1181-1191.
32. Isaka Y, Brees DK, Ikegaya K, et al: Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 1996;2:418-423.
33. Isaka Y, Akagi Y, Ando Y, et al: Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1999;55:465-475.
34. Zhou A, Ueno H, Shimomura M, et al: Blockade of TGF-beta action ameliorates renal dysfunction and histologic progression in anti-GBM nephritis. Kidney Int 2003;64:92-101.
35. Haviv YS, Takayama K, Nagi PA, et al: Modulation of renal glomerular disease using remote delivery of adenoviral-encoded solubletype II TGF-beta receptor fusion molecule. J Gene Med 2003;5:839-851.
36. Matsumoto K, Nakamura T: Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int 2001;59:2023-2038.
37. Yang J, Dai C, Liu Y: Systemic administration of naked plasmid encoding hepatocyte growth factor ameliorates chronic renal fibrosis in mice. Gene Ther 2001;8:1470-1479.
38. Yang J, Dai C, Liu Y: Hepatocyte growth factor suppresses renal interstitial myofibroblast activation and intercepts Smad signal transduction. Am J pathol 2003;163:621-632.
39. Yang J, Dai C, Liu Y: A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition. J Am Soc Nephrol 2005;16:68-78.
40. Gao X, Mae H, Ayabe N, et al: Hepatocyte growth factor gene therapy retards the progression of chronic obstructive nephropathy. Kidney Int 2002;62:1238-1248.
41. Mizui M, Isaka Y, Takabatake Y, et al: Electroporation-mediated HGF gene transfer ameliorated cyclosporine nephrotoxicity. Kidney Int 2004;65:2041-2053.
42. Herrero-Fresneda I, Torras J, Franquesa M, et al: HGF gene therapy attenuates renal allograft scarring by preventing the profibrotic inflammatory-induced mechanisms. Kidney Int 2006;70:265-274.
43. Isaka Y, Yamada K, Takabatake Y, et al: Electroporation-mediated HGF gene transfection protected the kidney against graft injury. Gene Ther 2005;12:815-820.
44. Nakamura H, Isaka Y, Tsujie M, et al: Electroporation-mediated PDGF receptor-IgG chimera gene transfer ameliorates experimental glomerulonephritis. Kidney Int 2001;59:2134-2145.
45. Yokoi H, Sugawara A, Mukoyama M, et al: Role of connective tissue growth factor in profibrotic action of transforming growth factor-beta a potential target for preventing renal fibrosis. Am J Kidney Dis 2001;38:S134-S138.
46. Yokoi H, Mukoyama M, Nagae T, et al: Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J Am Soc Nephrol 2004;15:1430-1440.
47. Carl M, Akagi Y, Weidner S, et al: Specific inhibition of Egr-1 prevents mesangial cell hypercellularity in experimental nephritis. Kidney Int 2003;63:1302-1312.
48. Nakamura H, Isaka Y, Tsujie M, et al: Introduction of DNA enzyme for Egr-1 into tubulointerstitial fibroblasts by electroporation reduced interstitial alpha-smooth muscle actin expression and fibrosis in unilateral ureteral obstruction (UUO) rats. Gene Ther 2002;9:495-502.
49. Takase O, Hirahashi J, Takayanagi A, et al: Gene transfer of truncated IkappaBalpha prevents tubulointerstitial injury. Kidney Int 2003;63:501-513.
50. Mizui M, Isaka Y, Takabatake Y, et al: Transcription factor Ets-1 is essential for mesangial matrix remodeling. Kidney Int 2006;70:298-305.
51. Daniel C, Takabatake Y, Mizui M, et al: Antisense oligonucleotides against thrombospondin-1 inhibit activation of tgf-beta in fibrotic renal disease in the rat in vivo. Am J Pathol 2003;163:1185-1192.
52. Cheng QL, Chen XM, Li F, et al: Effects of ICAM-1 antisense oligonucleotide on the tubulointerstitium in mice with unilateral ureteral obstruction. Kidney Int 2000;57:183-190.
53. Yamagishi H, Yokoo T, Imasawa T, et al: Genetically modified bone marrow-derived vehicle cells site specifically deliver an anti-inflammatory cytokine to inflamed interstitium of obstructive nephropathy. J Immunol 2001;166:609-616.
54. Furuichi K, Wada T, Iwata Y, et al: Gene therapy expressing amino-terminal truncated monocyte chemoattractant protein-1 prevents renal ischemia-reperfusion injury. J Am Soc Nephrol 2003;14:1066-1071.
55. Wada T, Furuichi K, Sakai N, et al: Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. J Am Soc Nephrol 2004;15:940-948.
56. Shimizu H, Maruyama S, Yuzawa Y, et al: Anti-monocyte chemoattractant protein-1 gene therapy attenuates renal injury induced by protein-overload proteinuria. J Am Soc Nephrol 2003;14:1496-1505.